<DOC>
	<DOC>NCT00308464</DOC>
	<brief_summary>The purpose of this study is to explore the safety, toleration and dose response of PHA-794428 after multiple weekly injections in male and female growth hormone deficient patients.</brief_summary>
	<brief_title>A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description>The study terminated on 10-Dec-2007. Pfizer's decision to terminate the program was due to cases of injection-site lipoatrophy that were reported in the clinical Phase 2 studies after a single injection of PHA 794428.</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male and female patients with severe AGHD. Hypopituitary patients must be on adequate hormone replacement therapy for at least 6 months. AGHD patients with uncontrolled pituitary tumor growth. Tumors within 3 mm of the optic chiasm. Patients with diabetes mellitus.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>